51
|
Cherney LT, Obrecht NM, Krylov SN. Theoretical modeling of masking DNA application in aptamer-facilitated biomarker discovery. Anal Chem 2013; 85:4157-64. [PMID: 23480390 DOI: 10.1021/ac400385v] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
In aptamer-facilitated biomarker discovery (AptaBiD), aptamers are selected from a library of random DNA (or RNA) sequences for their ability to specifically bind cell-surface biomarkers. The library is incubated with intact cells, and cell-bound DNA molecules are separated from those unbound and amplified by the polymerase chain reaction (PCR). The partitioning/amplification cycle is repeated multiple times while alternating target cells and control cells. Efficient aptamer selection in AptaBiD relies on the inclusion of masking DNA within the cell and library mixture. Masking DNA lacks primer regions for PCR amplification and is typically taken in excess to the library. The role of masking DNA within the selection mixture is to outcompete any nonspecific binding sequences within the initial library, thus allowing specific DNA sequences (i.e., aptamers) to be selected more efficiently. Efficient AptaBiD requires an optimum ratio of masking DNA to library DNA, at which aptamers still bind specific binding sites but nonaptamers within the library do not bind nonspecific binding sites. Here, we have developed a mathematical model that describes the binding processes taking place within the equilibrium mixture of masking DNA, library DNA, and target cells. An obtained mathematical solution allows one to estimate the concentration of masking DNA that is required to outcompete the library DNA at a desirable ratio of bound masking DNA to bound library DNA. The required concentration depends on concentrations of the library and cells as well as on unknown cell characteristics. These characteristics include the concentration of total binding sites on the cell surface, N, and equilibrium dissociation constants, K(nsL) and K(nsM), for nonspecific binding of the library DNA and masking DNA, respectively. We developed a theory that allows the determination of N, K(nsL), and K(nsM) based on measurements of EC50 values for cells mixed separately with the library and masking DNA (EC50 is the concentration of fluorescently labeled DNA at which half of the maximum fluorescence signal from DNA-bound cells is reached). We also obtained expressions for signals from bound DNA (measured by flow cytometry) in terms of N, K(nsL), and K(nsM). These expressions can be used for the verification of N, K(nsL), and K(nsM) values found from EC50 measurements. The developed procedure was applied to MCF-7 breast cancer cells, and corresponding values of N, K(nsL), and K(nsM) were established for the first time. The concentration of masking DNA required for AptaBiD with MCF-7 breast cancer cells was also estimated.
Collapse
Affiliation(s)
- Leonid T Cherney
- Department of Chemistry and Centre for Research on Biomolecular Interactions, York University, Toronto, Ontario M3J 1P3, Canada
| | | | | |
Collapse
|
52
|
Liu Q, Cobb JS, Johnson JL, Wang Q, Agar JN. Performance comparisons of nano-LC systems, electrospray sources and LC-MS-MS platforms. J Chromatogr Sci 2013; 52:120-7. [PMID: 23329739 DOI: 10.1093/chromsci/bms255] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Selecting a suitable nano-liquid chromatography system (LC), ionization source and mass spectrometer for LC-tandem mass spectrometry (MS-MS) studies is complicated by numerous competing technologies. This study compares four popular nano-LC systems, four ionization sources and three MS facilities that use completely different LC-MS-MS systems. Statistically significant differences in LC performance were identified with similarly performing Proxeon, Waters and Eksigent nanoLC-Ultra systems [retention time routinely at 0.7-0.9% relative standard deviation (RSD)], and all outperformed the Eksigent nanoLC-2D (RSD ∼2%). In addition, compatibility issues were identified between the Bruker HCT ion trap mass spectrometer and both the Eksigent nanoLC-2D and the Bruker nanoelectrospray source. The electrospray source itself had an unexpected and striking effect on chromatographic reproducibility on the Bruker HCT ion trap. The New Objective nanospray source significantly outperformed the Bruker nanospray source in retention time RSD (1% RSD versus 14% RSD, respectively); and the Bruker nebulized nanospray source outperformed both of these traditional, non-nebulized sources (0.5% RSD in retention time). Finally, to provide useful benchmarks for overall proteomics sensitivity, different LC-MS-MS platforms were compared by analyzing a range of concentrations of tryptic digests of bovine serum albumin at three MS facilities. The results indicate that similar sensitivity can be realized with a Bruker HCT-Ultra ion trap, a Thermo LTQ-Velos Linear ion trap and a Thermo LTQ-Orbitrap XL-ETD.
Collapse
|
53
|
Ananthi S, Venkatesh Prajna N, Lalitha P, Valarnila M, Dharmalingam K. Pathogen induced changes in the protein profile of human tears from Fusarium keratitis patients. PLoS One 2013; 8:e53018. [PMID: 23308132 PMCID: PMC3540078 DOI: 10.1371/journal.pone.0053018] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2012] [Accepted: 11/22/2012] [Indexed: 12/11/2022] Open
Abstract
Fusarium is the major causative agent of fungal infections leading to corneal ulcer (keratitis) in Southern India and other tropical countries. Keratitis caused by Fusarium is a difficult disease to treat unless antifungal therapy is initiated during the early stages of infection. In this study tear proteins were prepared from keratitis patients classified based on the duration of infection. Among the patients recruited, early infection (n = 35), intermediate (n = 20), late (n = 11), samples from five patients in each group were pooled for analysis. Control samples were a pool of samples from 20 patients. Proteins were separated on difference gel electrophoresis (DIGE) and the differentially expressed proteins were quantified using DeCyder software analysis. The following differentially expressed proteins namely alpha-1-antitrypsin, haptoglobin α2 chain, zinc-alpha-2-glycoprotein, apolipoprotein, albumin, haptoglobin precursor - β chain, lactoferrin, lacrimal lipocalin precursor, cystatin SA III precursor, lacritin precursor were identified using mass spectrometry. Variation in the expression level of some of the proteins was confirmed using western blot analysis. This is the first report to show stage specific tear protein profile in fungal keratitis patients. Validation of this data using a much larger sample set could lead to clinical application of these findings.
Collapse
Affiliation(s)
- Sivagnanam Ananthi
- Dr. G. Venkataswamy Eye Research Institute, Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India
| | | | - Prajna Lalitha
- Department of Microbiology, Aravind Eye Hospital, Aravind Eye Care System, Madurai, India
| | - Murugesan Valarnila
- Dr. G. Venkataswamy Eye Research Institute, Aravind Medical Research Foundation, Aravind Eye Care System, Madurai, India
| | | |
Collapse
|
54
|
Sokolowska I, Wetie AGN, Woods AG, Darie CC. Applications of Mass Spectrometry in Proteomics. Aust J Chem 2013. [DOI: 10.1071/ch13137] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Characterisation of proteins and whole proteomes can provide a foundation to our understanding of physiological and pathological states and biological diseases or disorders. Constant development of more reliable and accurate mass spectrometry (MS) instruments and techniques has allowed for better identification and quantification of the thousands of proteins involved in basic physiological processes. Therefore, MS-based proteomics has been widely applied to the analysis of biological samples and has greatly contributed to our understanding of protein functions, interactions, and dynamics, advancing our knowledge of cellular processes as well as the physiology and pathology of the human body. This review will discuss current proteomic approaches for protein identification and characterisation, including post-translational modification (PTM) analysis and quantitative proteomics as well as investigation of protein–protein interactions (PPIs).
Collapse
|
55
|
Rabilloud T, Triboulet S. Two-dimensional SDS-PAGE fractionation of biological samples for biomarker discovery. Methods Mol Biol 2013; 1002:151-165. [PMID: 23625402 DOI: 10.1007/978-1-62703-360-2_13] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Two-dimensional electrophoresis is still a very valuable tool in proteomics, due to its reproducibility and its ability to analyze complete proteins. However, due to its sensitivity to dynamic range issues, its most suitable use in the frame of biomarker discovery is not on very complex fluids such as plasma, but rather on more proximal, simpler fluids such as CSF, urine, or secretome samples. Here, we describe the complete workflow for the analysis of such dilute samples by two-dimensional electrophoresis, starting from sample concentration, then the two-dimensional electrophoresis step per se, ending with the protein detection by fluorescence.
Collapse
Affiliation(s)
- Thierry Rabilloud
- Chemistry and Biology of Metals Grenoble, CEA Grenoble, Grenoble, France
| | | |
Collapse
|
56
|
Chao TC, Hansmeier N. Microfluidic devices for high-throughput proteome analyses. Proteomics 2012; 13:467-79. [PMID: 23135952 DOI: 10.1002/pmic.201200411] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2012] [Revised: 09/06/2012] [Accepted: 10/05/2012] [Indexed: 12/14/2022]
Abstract
Over the last decades, microfabricated bioanalytical platforms have gained enormous interest due to their potential to revolutionize biological analytics. Their popularity is based on several key properties, such as high flexibility of design, low sample consumption, rapid analysis time, and minimization of manual handling steps, which are of interest for proteomics analyses. An ideal totally integrated chip-based microfluidic device could allow rapid automated workflows starting from cell cultivation and ending with MS-based proteome analysis. By reducing or eliminating sample handling and transfer steps and increasing the throughput of analyses these workflows would dramatically improve the reliability, reproducibility, and throughput of proteomic investigations. While these complete devices do not exist for routine use yet, many improvements have been made in the translation of proteomic sample handling and separation steps into microfluidic formats. In this review, we will focus on recent developments and strategies to enable and integrate proteomic workflows into microfluidic devices.
Collapse
Affiliation(s)
- Tzu-Chiao Chao
- Department of Chemistry and Biochemistry, Arizona State University, Tempe, AZ, USA
| | | |
Collapse
|
57
|
Alawieh A, Zaraket FA, Li JL, Mondello S, Nokkari A, Razafsha M, Fadlallah B, Boustany RM, Kobeissy FH. Systems biology, bioinformatics, and biomarkers in neuropsychiatry. Front Neurosci 2012; 6:187. [PMID: 23269912 PMCID: PMC3529307 DOI: 10.3389/fnins.2012.00187] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2012] [Accepted: 12/06/2012] [Indexed: 11/13/2022] Open
Abstract
Although neuropsychiatric (NP) disorders are among the top causes of disability worldwide with enormous financial costs, they can still be viewed as part of the most complex disorders that are of unknown etiology and incomprehensible pathophysiology. The complexity of NP disorders arises from their etiologic heterogeneity and the concurrent influence of environmental and genetic factors. In addition, the absence of rigid boundaries between the normal and diseased state, the remarkable overlap of symptoms among conditions, the high inter-individual and inter-population variations, and the absence of discriminative molecular and/or imaging biomarkers for these diseases makes difficult an accurate diagnosis. Along with the complexity of NP disorders, the practice of psychiatry suffers from a "top-down" method that relied on symptom checklists. Although checklist diagnoses cost less in terms of time and money, they are less accurate than a comprehensive assessment. Thus, reliable and objective diagnostic tools such as biomarkers are needed that can detect and discriminate among NP disorders. The real promise in understanding the pathophysiology of NP disorders lies in bringing back psychiatry to its biological basis in a systemic approach which is needed given the NP disorders' complexity to understand their normal functioning and response to perturbation. This approach is implemented in the systems biology discipline that enables the discovery of disease-specific NP biomarkers for diagnosis and therapeutics. Systems biology involves the use of sophisticated computer software "omics"-based discovery tools and advanced performance computational techniques in order to understand the behavior of biological systems and identify diagnostic and prognostic biomarkers specific for NP disorders together with new targets of therapeutics. In this review, we try to shed light on the need of systems biology, bioinformatics, and biomarkers in neuropsychiatry, and illustrate how the knowledge gained through these methodologies can be translated into clinical use providing clinicians with improved ability to diagnose, manage, and treat NP patients.
Collapse
Affiliation(s)
- Ali Alawieh
- Department of Biochemistry, College of Medicine, American University of Beirut Beirut, Lebanon
| | | | | | | | | | | | | | | | | |
Collapse
|
58
|
Tabb DL. Quality assessment for clinical proteomics. Clin Biochem 2012; 46:411-20. [PMID: 23246537 DOI: 10.1016/j.clinbiochem.2012.12.003] [Citation(s) in RCA: 55] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2012] [Revised: 12/01/2012] [Accepted: 12/03/2012] [Indexed: 12/21/2022]
Abstract
Proteomics has emerged from the labs of technologists to enter widespread application in clinical contexts. This transition, however, has been hindered by overstated early claims of accuracy, concerns about reproducibility, and the challenges of handling batch effects properly. New efforts have produced sets of performance metrics and measurements of variability that establish sound expectations for experiments in clinical proteomics. As researchers begin incorporating these metrics in a quality by design paradigm, the variability of individual steps in experimental pipelines will be reduced, regularizing overall outcomes. This review discusses the evolution of quality assessment in 2D gel electrophoresis, mass spectrometry-based proteomic profiling, tandem mass spectrometry-based protein inventories, and proteomic quantitation. Taken together, the advances in each of these technologies are establishing databases that will be increasingly useful for decision-making in clinical experimentation.
Collapse
Affiliation(s)
- David L Tabb
- Department of Biomedical Informatics, Vanderbilt University, USA.
| |
Collapse
|
59
|
Raad M, El Tal T, Gul R, Mondello S, Zhang Z, Boustany RM, Guingab J, Wang KK, Kobeissy F. Neuroproteomics approach and neurosystems biology analysis: ROCK inhibitors as promising therapeutic targets in neurodegeneration and neurotrauma. Electrophoresis 2012; 33:3659-68. [DOI: 10.1002/elps.201200470] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2012] [Revised: 10/07/2012] [Accepted: 10/08/2012] [Indexed: 12/14/2022]
Affiliation(s)
- Mohamad Raad
- Department of Biochemistry and Molecular Genetics; Faculty of Medicine; American University of Beirut; Beirut; Lebanon
| | - Tala El Tal
- Faculty of Medicine; American University of Beirut; Beirut; Lebanon
| | - Rukhsana Gul
- Department of Internal Medicine; Harry S. Truman Veterans Affairs Medical Center; University of Missouri; Columbia; MO; USA
| | - Stefania Mondello
- Center of Innovative Research Banyan Biomarkers Inc.; Alachua; FL; USA
| | - Zhiqun Zhang
- Department of Psychiatry; University of Florida; Gainesville; FL; USA
| | | | - Joy Guingab
- Center of Innovative Research Banyan Biomarkers Inc.; Alachua; FL; USA
| | - Kevin K. Wang
- Department of Psychiatry; University of Florida; Gainesville; FL; USA
| | | |
Collapse
|
60
|
Baracat-Pereira MC, de Oliveira Barbosa M, Magalhães MJ, Carrijo LC, Games PD, Almeida HO, Sena Netto JF, Pereira MR, de Barros EG. Separomics applied to the proteomics and peptidomics of low-abundance proteins: Choice of methods and challenges - A review. Genet Mol Biol 2012; 35:283-91. [PMID: 22802713 PMCID: PMC3392880 DOI: 10.1590/s1415-47572012000200009] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
The enrichment and isolation of proteins are considered limiting steps in proteomic studies. Identification of proteins whose expression is transient, those that are of low-abundance, and of natural peptides not described in databases, is still a great challenge. Plant extracts are in general complex, and contaminants interfere with the identification of proteins involved in important physiological processes, such as plant defense against pathogens. This review discusses the challenges and strategies of separomics applied to the identification of low-abundance proteins and peptides in plants, especially in plants challenged by pathogens. Separomics is described as a group of methodological strategies for the separation of protein molecules for proteomics. Several tools have been used to remove highly abundant proteins from samples and also non-protein contaminants. The use of chromatographic techniques, the partition of the proteome into subproteomes, and an effort to isolate proteins in their native form have allowed the isolation and identification of rare proteins involved in different processes.
Collapse
Affiliation(s)
- Maria Cristina Baracat-Pereira
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Meire de Oliveira Barbosa
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Marcos Jorge Magalhães
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Lanna Clicia Carrijo
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Patrícia Dias Games
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - Hebréia Oliveira Almeida
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | - José Fabiano Sena Netto
- Departamento de Bioquímica e Biologia Molecular, Instituto de Biotecnologia Aplicada à Agropecuária, Universidade Federal de Viçosa, Viçosa, MG, Brazil
| | | | | |
Collapse
|
61
|
Lopes LV, Kussmann M. Proteomics at the interface of psychology, gut physiology and dysfunction: an underexploited approach that deserves expansion. Expert Rev Proteomics 2012; 8:605-14. [PMID: 21999831 DOI: 10.1586/epr.11.50] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Gut functions such as digestion and absorption are essential to life and the emerging insights into the gut-brain axis - that is, the cross talk between the enteric and CNS - point towards critical links between (eating) behavior, psychology, whole body and gut physiology, and digestive and overall health. While proteomics is ideally positioned to shed more light on these interactions, be it applied to the periphery (e.g., blood) or the locus of action (i.e., the gut), it is to date largely underexploited, mainly because of challenging sampling and tissue complexity. In view of the contrast between potential and current delivery of proteomics in the context of intestinal health, this article briefs the reader on the state-of-the-art of molecular intestinal research, reviews current proteomic studies (explicitly focusing on the most recent ones that target inflammatory bowel disease patient samples) and argues for an expansion of this research field.
Collapse
Affiliation(s)
- Luísa V Lopes
- Neurosciences Unit, Instituto de Medicina Molecular, Av. Prof. Egas Moniz, 1640-028 Lisboa, Portugal.
| | | |
Collapse
|
62
|
Chao TC, Hansmeier N. The current state of microbial proteomics: Where we are and where we want to go. Proteomics 2012; 12:638-50. [DOI: 10.1002/pmic.201100381] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2011] [Revised: 08/15/2011] [Accepted: 08/22/2011] [Indexed: 11/11/2022]
|
63
|
Kobeissy F, Alawieh A, Mondello S, Boustany RM, Gold MS. Biomarkers in psychiatry: how close are we? Front Psychiatry 2012; 3:114. [PMID: 23316174 PMCID: PMC3539768 DOI: 10.3389/fpsyt.2012.00114] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2012] [Accepted: 12/17/2012] [Indexed: 12/13/2022] Open
Affiliation(s)
- Firas Kobeissy
- Division of Addiction Medicine, Department of Psychiatry, Center for Neuroproteomics and Biomarkers Research, University of Florida Gainesville, FL, USA
| | | | | | | | | |
Collapse
|
64
|
Findeisen P, Neumaier M. Functional protease profiling for diagnosis of malignant disease. Proteomics Clin Appl 2011; 6:60-78. [PMID: 22213637 DOI: 10.1002/prca.201100058] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2011] [Revised: 09/27/2011] [Accepted: 10/19/2011] [Indexed: 12/24/2022]
Abstract
Clinical proteomic profiling by mass spectrometry (MS) aims at uncovering specific alterations within mass profiles of clinical specimens that are of diagnostic value for the detection and classification of various diseases including cancer. However, despite substantial progress in the field, the clinical proteomic profiling approaches have not matured into routine diagnostic applications so far. Their limitations are mainly related to high-abundance proteins and their complex processing by a multitude of endogenous proteases thus making rigorous standardization difficult. MS is biased towards the detection of low-molecular-weight peptides. Specifically, in serum specimens, the particular fragments of proteolytically degraded proteins are amenable to MS analysis. Proteases are known to be involved in tumour progression and tumour-specific proteases are released into the blood stream presumably as a result of invasive progression and metastasis. Thus, the determination of protease activity in clinical specimens from patients with malignant disease can offer diagnostic and also therapeutic options. The identification of specific substrates for tumour proteases in complex biological samples is challenging, but proteomic screens for proteases/substrate interactions are currently experiencing impressive progress. Such proteomic screens include peptide-based libraries, differential isotope labelling in combination with MS, quantitative degradomic analysis of proteolytically generated neo-N-termini, monitoring the degradation of exogenous reporter peptides with MS, and activity-based protein profiling. In the present article, we summarize and discuss the current status of proteomic techniques to identify tumour-specific protease-substrate interactions for functional protease profiling. Thereby, we focus on the potential diagnostic use of the respective approaches.
Collapse
Affiliation(s)
- Peter Findeisen
- Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany.
| | | |
Collapse
|
65
|
Taverna D, Nanney LB, Pollins AC, Sindona G, Caprioli R. Multiplexed molecular descriptors of pressure ulcers defined by imaging mass spectrometry. Wound Repair Regen 2011; 19:734-44. [PMID: 22092844 DOI: 10.1111/j.1524-475x.2011.00738.x] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2011] [Accepted: 09/08/2011] [Indexed: 11/28/2022]
Abstract
The pathogenesis of impaired healing within pressure ulcers remains poorly characterized and rarely examined. We describe the results of a pilot study that applies matrix-assisted laser desorption/ionization imaging mass spectrometry technology for direct tissue analysis to evaluate proteomic signatures ranging from 2 to 20 kDa and phospholipids from 300-1,200 Da in focal regions within the wound microenvironment. Distinguishing molecular differences were apparent between upper vs. lower regions of ulcers and further contrasted against adjacent dermis and epidermal margins using protein profiles, ion density maps, principal component analysis and significant analysis of microarrays. Several proteins previously uncharacterized in pressure ulcers, the α-defensins (human neutrophil peptide [HNP]-1, -2, -3), are potential markers indicating whether the wound status is improving or being prolonged in a deleterious, chronic state. Thymosin β4 appears to be a favorable protein marker showing higher relative levels in adjacent dermis and maturing areas of the wound bed. Lipidomic examination revealed the presence of major lipid classes: glycerophosphocholines, glycerophosphoglycerols, glycerophosphoinositols, and triacylglycerols. Our pilot data examined from either a global perspective using proteomic or lipidomic signatures or as individual distributions reveal that imaging mass spectrometry technology can be effectively used for discovery and spatial mapping of molecular disturbances within the microenvironment of chronic wounds.
Collapse
Affiliation(s)
- Domenico Taverna
- Department of Chemistry, Universita' della Calabria, Arcavacata di Rende, Cs, Italy
| | | | | | | | | |
Collapse
|
66
|
Apolipoprotein A1 and C-terminal fragment of α-1 antichymotrypsin are candidate plasma biomarkers associated with acute renal allograft rejection. Transplantation 2011; 92:388-95. [PMID: 21730889 DOI: 10.1097/tp.0b013e318225db6a] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
BACKGROUND Current diagnostic methods of renal allograft rejection are neither sensitive nor specific. Needle biopsies are invasive and associated with patient morbidity. Thus, it is desirable to develop noninvasive tests to predict and diagnose rejection. METHODS Using a case-control approach, surface-enhanced laser desorption/ionization time-of-flight mass spectrometry was used to identify plasma proteins associated with renal allograft rejection. From each rejection patient (n=16), two plasma samples (one near the biopsy date and the other at a time postbiopsy) were compared. Biopsy-confirmed nonrejection patients (n=48) were further analyzed as controls. Antibody-based quantitative enzyme-linked immunosorbent assay was performed to validate candidate biomarker apolipoprotein A1 (Apo A1) in a subset of the original and a second cohort of biopsy-confirmed rejection (n=40) and nonrejection (n=70) patients. RESULTS Twenty-two proteins/peptides showed significant differences between rejection and postrejection samples. Peptides 5191 Da and 4467 Da detected rejection with 100% sensitivity and 94% specificity. The 4467 Da peptide was identified as the C-terminal fragment of α-1 antichymotrypsin and a 28 kDa protein was determined as Apo A1. Both protein levels were significantly lower at rejection compared with postrejection. Protein levels of nonrejection patients were similar to the postrejection samples. Apo A1 enzyme-linked immunosorbent assay results showed significantly lower Apo A1 levels (P=0.001 for the original and P=4.14E-11 for the second cohort) at the time of rejection compared with nonrejection which coincides with the SELDI findings. CONCLUSIONS Together α-1 antichymotrypsin, Apo A1, and the unidentified 5191 Da peptide provide a plasma molecular profile, and this is associated with acute cellular renal allograft rejection.
Collapse
|
67
|
Forshed J, Johansson HJ, Pernemalm M, Branca RMM, Sandberg A, Lehtiö J. Enhanced information output from shotgun proteomics data by protein quantification and peptide quality control (PQPQ). Mol Cell Proteomics 2011; 10:M111.010264. [PMID: 21734112 DOI: 10.1074/mcp.m111.010264] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
We present a tool to improve quantitative accuracy and precision in mass spectrometry based on shotgun proteomics: protein quantification by peptide quality control, PQPQ. The method is based on the assumption that the quantitative pattern of peptides derived from one protein will correlate over several samples. Dissonant patterns arise either from outlier peptides or because of the presence of different protein species. By correlation analysis, protein quantification by peptide quality control identifies and excludes outliers and detects the existence of different protein species. Alternative protein species are then quantified separately. By validating the algorithm on seven data sets related to different cancer studies we show that data processing by protein quantification by peptide quality control improves the information output from shotgun proteomics. Data from two labeling procedures and three different instrumental platforms was included in the evaluation. With this unique method using both peptide sequence data and quantitative data we can improve the quantitative accuracy and precision on the protein level and detect different protein species.
Collapse
Affiliation(s)
- Jenny Forshed
- The Science for Life Laboratory Stockholm and Department of Oncology-Pathology, Mass spectrometry and Proteomics, Science for Life Laboratory, Box 1031, 17121 Solna, Sweden.
| | | | | | | | | | | |
Collapse
|
68
|
Zhong L, Taylor D, Begg D, Whittington R. Biomarker discovery for ovine paratuberculosis (Johne's disease) by proteomic serum profiling. Comp Immunol Microbiol Infect Dis 2011; 34:315-26. [DOI: 10.1016/j.cimid.2011.03.001] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2010] [Revised: 02/17/2011] [Accepted: 03/10/2011] [Indexed: 10/18/2022]
|
69
|
Nutriproteomics: technologies and applications for identification and quantification of biomarkers and ingredients. Proc Nutr Soc 2011; 70:351-64. [DOI: 10.1017/s0029665111000528] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
Nutrition refers to the process by which a living organism ingests and digests food and uses the nutrients therein for growth, tissue maintenance and all other functions essential to life. Food components interact with our body at molecular, cellular, organ and system level. Nutrients come in complex mixtures, in which the presence and concentration of single compounds as well as their interactions with other compounds and the food matrix influence their bioavailability and bioefficacy. Traditionally, nutrition research mainly concentrated on supplying nutrients of quality to nourish populations and on preventing specific nutrient deficiencies. More recently, it investigates health-related aspects of individual ingredients or of complete diets, in view of health promotion, performance optimisation, disease prevention and risk assessment. This review focuses on proteins and peptides, their role as nutrients and biomarkers and on the technologies developed for their analysis. In the first part of this review, we provide insights into the way proteins are currently characterised and analysed using classical and emerging proteomic approaches. The scope of the second part is to review major applications of proteomics to nutrition, from characterisation of food proteins and peptides, via investigation of health-related food benefits to understanding disease-related mechanisms.
Collapse
|
70
|
Vestal ML. The future of biological mass spectrometry. JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY 2011; 22:953-959. [PMID: 21953036 DOI: 10.1007/s13361-011-0108-x] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/14/2011] [Accepted: 02/15/2011] [Indexed: 05/31/2023]
Abstract
Biological applications of mass spectrometry have grown exponentially since the discovery of MALDI and electrospray ionization techniques. This growth has been further fueled by the massive volume of DNA sequence information that is now available. An ambitious goal of some of this research is to monitor the level and modification of all proteins and metabolites in a biological sample such as plasma. A major research effort in mass spectrometry and related disciplines has been expended over the past several years toward reaching this and other less ambitious goals, and considerable progress has been made; but the presently available tools are clearly not sufficient for these very difficult tasks. In this "critical insight" discussion we suggest that recent advances in time-of-flight (TOF) technology with MALDI ionization may provide some important new tools for achieving the goals of biological research.
Collapse
|
71
|
Rabilloud T, Hochstrasser D, Simpson RJ. Is a gene-centric human proteome project the best way for proteomics to serve biology? Proteomics 2010; 10:3067-72. [PMID: 20648483 DOI: 10.1002/pmic.201000220] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
With the recent developments in proteomic technologies, a complete human proteome project (HPP) appears feasible for the first time. However, there is still debate as to how it should be designed and what it should encompass. In "proteomics speak", the debate revolves around the central question as to whether a gene-centric or a protein-centric proteomics approach is the most appropriate way forward. In this paper, we try to shed light on what these definitions mean, how large-scale proteomics such as a HPP can insert into the larger omics chorus, and what we can reasonably expect from a HPP in the way it has been proposed so far.
Collapse
Affiliation(s)
- Thierry Rabilloud
- Biochemistry and Biophysics of Integrated Systems, UMR CNRS-CEA-UJF 5092, CEA Grenoble, iRTSV/BSBBSI, Grenoble, France.
| | | | | |
Collapse
|
72
|
Garbis SD, Roumeliotis TI, Tyritzis SI, Zorpas KM, Pavlakis K, Constantinides CA. A Novel Multidimensional Protein Identification Technology Approach Combining Protein Size Exclusion Prefractionation, Peptide Zwitterion−Ion Hydrophilic Interaction Chromatography, and Nano-Ultraperformance RP Chromatography/nESI-MS2 for the in-Depth Analysis of the Serum Proteome and Phosphoproteome: Application to Clinical Sera Derived from Humans with Benign Prostate Hyperplasia. Anal Chem 2010; 83:708-18. [DOI: 10.1021/ac102075d] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Spiros D. Garbis
- Center for Basic Research, Division of Biotechnology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Theodoros I. Roumeliotis
- Center for Basic Research, Division of Biotechnology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Stavros I. Tyritzis
- Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece
| | - Kostas M. Zorpas
- Center for Basic Research, Division of Biotechnology, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
| | - Kitty Pavlakis
- Department of Urology, Athens University Medical School, “LAIKO” Hospital, Athens, Greece
| | | |
Collapse
|
73
|
Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010; 17:493-506. [PMID: 21044772 DOI: 10.1053/j.ackd.2010.09.004] [Citation(s) in RCA: 60] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2010] [Accepted: 09/21/2010] [Indexed: 01/10/2023]
Abstract
Use of capillary electrophoresis coupled to mass spectrometry (CE-MS) technology in proteome analysis has increased, with a focus on the identification of biomarker peptides in clinical proteomics. Among the reported applications, the main focus is on the urinary biomarkers for kidney disease. In this review, we discuss the principal, theoretical, and practical obstacles that are encountered when using CE-MS for the analysis of body fluids for biomarker discovery. We present several examples of a successful application of CE-MS for biomarker discovery in kidney disease, implications for disease diagnosis, prognosis, and therapy evaluation, and will also discuss current challenges and possible future improvements.
Collapse
|
74
|
Kussmann M, Panchaud A, Affolter M. Proteomics in nutrition: status quo and outlook for biomarkers and bioactives. J Proteome Res 2010; 9:4876-87. [PMID: 20718507 DOI: 10.1021/pr1004339] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Food and beverages are the only physical matter we take into our body, if we disregard the air we inhale and the drugs we may have to apply. While traditional nutrition research has aimed at providing nutrients to nourish populations and preventing specific nutrient deficiencies, it more recently explores health-related aspects of individual bioactive components as well as entire diets and this at group rather than population level. The new era of nutrition research translates empirical knowledge to evidence-based molecular science. Modern nutrition research focuses on promoting health, preventing or delaying the onset of disease, optimizing performance, and assessing risk. Personalized nutrition is a conceptual analogue to personalized medicine and means adapting food to individual needs. Nutrigenomics and nutrigenetics build the science foundation for understanding human variability in preferences, requirements, and responses to diet and may become the future tools for consumer assessment motivated by personalized nutritional counseling for health maintenance and disease prevention. The scope of this paper is to review the current and future aspects of nutritional proteomics, focusing on the two main outputs: identification of health biomarkers and analysis of food bioactives.
Collapse
Affiliation(s)
- Martin Kussmann
- Functional Genomics Group, Department of BioAnalytical Sciences, Nestlé Research Center, Lausanne, Switzerland.
| | | | | |
Collapse
|
75
|
Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 2010; 5:e13421. [PMID: 20975990 PMCID: PMC2958112 DOI: 10.1371/journal.pone.0013421] [Citation(s) in RCA: 107] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2010] [Accepted: 09/13/2010] [Indexed: 11/19/2022] Open
Abstract
Background Urine proteome analysis is rapidly emerging as a tool for diagnosis and prognosis in disease states. For diagnosis of diabetic nephropathy (DN), urinary proteome analysis was successfully applied in a pilot study. The validity of the previously established proteomic biomarkers with respect to the diagnostic and prognostic potential was assessed on a separate set of patients recruited at three different European centers. In this case-control study of 148 Caucasian patients with diabetes mellitus type 2 and duration ≥5 years, cases of DN were defined as albuminuria >300 mg/d and diabetic retinopathy (n = 66). Controls were matched for gender and diabetes duration (n = 82). Methodology/Principal Findings Proteome analysis was performed blinded using high-resolution capillary electrophoresis coupled with mass spectrometry (CE-MS). Data were evaluated employing the previously developed model for DN. Upon unblinding, the model for DN showed 93.8% sensitivity and 91.4% specificity, with an AUC of 0.948 (95% CI 0.898-0.978). Of 65 previously identified peptides, 60 were significantly different between cases and controls of this study. In <10% of cases and controls classification by proteome analysis not entirely resulted in the expected clinical outcome. Analysis of patient's subsequent clinical course revealed later progression to DN in some of the false positive classified DN control patients. Conclusions These data provide the first independent confirmation that profiling of the urinary proteome by CE-MS can adequately identify subjects with DN, supporting the generalizability of this approach. The data further establish urinary collagen fragments as biomarkers for diabetes-induced renal damage that may serve as earlier and more specific biomarkers than the currently used urinary albumin.
Collapse
|
76
|
Two-dimensional gel electrophoresis in proteomics: Past, present and future. J Proteomics 2010; 73:2064-77. [PMID: 20685252 DOI: 10.1016/j.jprot.2010.05.016] [Citation(s) in RCA: 288] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2010] [Revised: 05/20/2010] [Accepted: 05/25/2010] [Indexed: 12/14/2022]
Abstract
Two-dimensional gel electrophoresis has been instrumental in the birth and developments of proteomics, although it is no longer the exclusive separation tool used in the field of proteomics. In this review, a historical perspective is made, starting from the days where two-dimensional gels were used and the word proteomics did not even exist. The events that have led to the birth of proteomics are also recalled, ending with a description of the now well-known limitations of two-dimensional gels in proteomics. However, the often-underestimated advantages of two-dimensional gels are also underlined, leading to a description of how and when to use two-dimensional gels for the best in a proteomics approach. Taking support of these advantages (robustness, resolution, and ability to separate entire, intact proteins), possible future applications of this technique in proteomics are also mentioned.
Collapse
|
77
|
Ben Ameur R, Molina L, Bolvin C, Kifagi C, Jarraya F, Ayadi H, Molina F, Granier C. Proteomic approaches for discovering biomarkers of diabetic nephropathy. Nephrol Dial Transplant 2010; 25:2866-75. [PMID: 20472580 DOI: 10.1093/ndt/gfq258] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
|
78
|
Armenta JM, Perez M, Yang X, Shapiro D, Reed D, Tuli L, Finkielstein CV, Lazar IM. Fast proteomic protocol for biomarker fingerprinting in cancerous cells. J Chromatogr A 2010; 1217:2862-70. [PMID: 20307887 PMCID: PMC2856699 DOI: 10.1016/j.chroma.2010.02.065] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2009] [Revised: 02/11/2010] [Accepted: 02/24/2010] [Indexed: 12/21/2022]
Abstract
The advance of novel technologies that will enable the detection of large sets of biomarker proteins, to greatly improve the sensitivity and specificity of an assay, represents a major objective in biomedical research. To demonstrate the power of mass spectrometry (MS) detection for large-scale biomarker screening in cancer research, a simple, one-step approach for fast biomarker fingerprinting in complex cellular extracts is described. MCF-7 breast cancer cells were used as a model system. Fast proteomic profiling of whole cellular extracts was achieved on a linear trap quadrupole (LTQ) mass spectrometer by one of the following techniques: (a) data-dependent liquid chromatography (LC)-MS/MS of un-labeled cell extracts, (b) data-dependent LC-MS/MS with pulsed Q dissociation (PQD) detection of iTRAQ labeled samples, and (c) multiple reaction monitoring (MRM)-MS of low abundant proteins that could not be detected with data-dependent MS/MS. The data-dependent LC-MS/MS analysis of MCF-7 cells enabled the identification of 796 proteins (p<0.001) and the simultaneous detection of 156 previously reported putative cancer biomarkers. PQD detection of iTRAQ labeled cells resulted in the detection of 389 proteins and 64 putative biomarkers. MRM-MS analysis enabled the successful monitoring of a panel of low-abundance proteins in one single experiment, highlighting the utility of this technique for targeted analysis in cancer investigations. These results demonstrate that MS-based technologies relying on a one-step separation protocol have the potential to revolutionize biomarker research and screening applications by enabling fast, sensitive and reliable detection of large panels of putative biomarkers. To further stimulate the exploration of proteins that have been previously reported in the literature to be differentially expressed in a variety of cancers, an extensive list of approximately 1100 candidate biomarkers has been compiled and included in the manuscript.
Collapse
Affiliation(s)
- Jenny M Armenta
- Virginia Bioinformatics Institute, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061, USA.
| | | | | | | | | | | | | | | |
Collapse
|
79
|
Chao TC, Hansmeier N, Halden RU. Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery. J Proteomics 2010; 73:1641-6. [PMID: 20399287 DOI: 10.1016/j.jprot.2010.04.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2010] [Revised: 04/07/2010] [Accepted: 04/09/2010] [Indexed: 01/24/2023]
Abstract
The use of proteomics to profile biological fluids and identify therein biomarkers for cancer and other diseases was initially received with considerable excitement. However, results have fallen short of the expectations. Traditionally, protein biomarkers have been identified by measurement of relative expression changes between case and control samples from which differentially expressed proteins are then considered to represent biomarker candidates. We argue that current individual proteomics-based biomarker discovery studies lack the statistical strength for the identification of high-confidence biomarkers. Instead, multi-group efforts are necessary to facilitate the generation of sufficient sample sizes. This is contingent on the ability to collate and cross-compare data from different studies, which will require the use of a common metric or standards. Though profound, the technical challenges for absolute protein quantification can be overcome. The use of matrix specific, shared standards for absolute quantitation presents an opportunity to facilitate the much needed, but currently impossible, comparisons of different studies. In addition to community-wide approaches to standardize pre-analytical biomarker research studies, it is also important to establish means to integrate experimental data from different studies in order to assess the usefulness of proposed biomarkers with sufficient statistical certainty.
Collapse
|
80
|
Wang C, Zhou J, Wang S, Ye M, Jiang C, Fan G, Zou H. Combined Comparative and Chemical Proteomics on the Mechanisms of levo-Tetrahydropalmatine-Induced Antinociception in the Formalin Test. J Proteome Res 2010; 9:3225-34. [DOI: 10.1021/pr1001274] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Chen Wang
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Jiangrui Zhou
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Shuowen Wang
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Mingliang Ye
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Chunlei Jiang
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Guorong Fan
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| | - Hanfa Zou
- Department of Pharmaceutical Analysis, School of Pharmacy, Second Military Medical University, No.325 Guohe Road, Shanghai 200433, People's Republic of China, Division of Biotechnology, Dalian Institute of Chemical Physics, CAS, No.457 Zhongshan Road, Dalian 116023, People's Republic of China, Laboratory of Stress Medicine, Department of Nautical Medicine, Second Military Medical University, No.800 Xiangyin Road, Shanghai 200433, People's Republic of China, and Shanghai Key Laboratory for Pharmaceutical
| |
Collapse
|
81
|
Albuquerque LM, Trugilho MRO, Chapeaurouge A, Jurgilas PB, Bozza PT, Bozza FA, Perales J, Neves-Ferreira AGC. Two-dimensional difference gel electrophoresis (DiGE) analysis of plasmas from dengue fever patients. J Proteome Res 2010; 8:5431-41. [PMID: 19845402 DOI: 10.1021/pr900236f] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Dengue fever is the world's most important arthropod-born viral disease affecting humans. To contribute to a better understanding of its pathogenesis, this study aims to identify proteins differentially expressed in plasmas from severe dengue fever patients relative to healthy donors. The use of 2-D Fluorescence Difference Gel Electrophoresis to analyze plasmas depleted of six high-abundance proteins (albumin, IgG, antitrypsin, IgA, transferrin and haptoglobin) allowed for the detection of 73 differentially expressed protein spots (n = 13, p < 0.01), of which 37 could be identified by mass spectrometry. These 37 spots comprised a total of 14 proteins, as follows: 7 had increased expression in plasmas from dengue fever patients (C1 inhibitor, alpha1-antichymotrypsin, vitamin D-binding protein, fibrinogen gamma-chain, alpha1-acid glycoprotein, apolipoprotein J and complement component C3c), while 7 others had decreased expression in the same samples (alpha-2 macroglobulin, prothrombin, histidine-rich glycoprotein, apolipoproteins A-IV and A-I, transthyretin and complement component C3b). The possible involvement of these proteins in the inflammatory process triggered by dengue virus infection and in the repair mechanisms of vascular damage occurring in this pathology is discussed in this study.
Collapse
Affiliation(s)
- Lidiane M Albuquerque
- Lab Toxinologia and Lab. Imunofarmacologia, Pavilhao Ozorio de Almeida, Instituto Oswaldo Cruz and Instituto de Pesquisa Clinica Evandro Chagas, Fiocruz, Av. Brasil 4365, 21040-900 Rio de Janeiro, Brazil
| | | | | | | | | | | | | | | |
Collapse
|
82
|
Abstract
To investigate changes in protein expression by proteomic analysis in the sera of patients with sepsis and to identify new biomarkers of sepsis. A total of 45 consecutive patients with severe sepsis or septic shock (sepsis group), 22 healthy volunteers, and 23 patients undergoing off-pump coronary artery bypass grafting (control group). Serum samples from eight patients of each group underwent proteomic analysis involving removal of 12 major proteins and subsequent reversed-phase high-performance liquid chromatography fractionation and one-dimensional electrophoresis. The intensity of 41 bands (with 12 proteins identified) increased and that of 42 bands (with 22 proteins identified) decreased in the sepsis group. Results of proteomic analysis successfully validated by Western blotting and/or enzyme-linked immunosorbent assay for three proteins (YKL-40, lipocalin 2, and S100A9) increased in the sepsis group as well as two proteins (retinol-binding protein, vitamin D-binding protein) decreased. Serum YKL-40 levels (sYKL-40) on intensive care unit (ICU) admission were assessed by enzyme-linked immunosorbent assay between the two groups; resulting YKL-40 was significantly higher in the sepsis group (P < 0.001). Furthermore, sYKL-40 on ICU admission was significantly higher in patients with positive blood culture (P < 0.005), patients with septic shock (P < 0.05), and patients requiring continuous hemodiafiltration (P < 0.05) or hydrocortisone replacement therapy (P < 0.005) during subsequent treatment. A positive correlation between sYKL-40 and blood IL-6 level on ICU admission was noted in the sepsis group (r = 0.465, P < 0.01). YKL-40 identified by proteomic analysis is considered as a biomarker of sepsis. However, further investigation is needed to clarify its roles and clinical usefulness as a biomarker.
Collapse
|
83
|
Findeisen P, Neumaier M. Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem Lab Med 2009; 47:666-84. [PMID: 19445650 DOI: 10.1515/cclm.2009.159] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Proteomics analysis has been heralded as a novel tool for identifying new and specific biomarkers that may improve diagnosis and monitoring of various disease states. Recent years have brought a number of proteomics profiling technologies. Although proteomics profiling has resulted in the detection of disease-associated differences and modification of proteins, current proteomics technologies display certain limitations that are hampering the introduction of these new technologies into clinical laboratory diagnostics and routine applications. In this review, we summarize current advances in mass spectrometry based biomarker discovery. The promises and challenges of this new technology are discussed with particular emphasis on diagnostic perspectives of mass-spectrometry based proteomics profiling for malignant diseases.
Collapse
Affiliation(s)
- Peter Findeisen
- Institute for Clinical Chemistry, Medical Faculty Mannheim of the University of Heidelberg, Heidelberg, Germany.
| | | |
Collapse
|
84
|
Ang CS, Rothacker J, Patsiouras H, Burgess AW, Nice EC. Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. J Chromatogr A 2009; 1217:3330-40. [PMID: 19875126 DOI: 10.1016/j.chroma.2009.10.007] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2009] [Revised: 09/30/2009] [Accepted: 10/02/2009] [Indexed: 12/18/2022]
Abstract
Tumor related products shed into the feces offer a potential source of biomarkers for the detection of colorectal cancer (CRC). Using SDS-PAGE followed by nanoflow reversed-phased LC-MS/MS to analyse fecal samples from Apc(Min/+) mice (that develop spontaneous multiple intestinal neoplasia with age) we have identified 336 proteins (115 proteins of murine origin, 201 from fecal bacteria, 18 associated with food intake and 2 of apparent parasitic origin). 75% of the murine proteins identified in this study are predicted to be extracellular or associated with the cell plasma membrane. Of these proteins, a number of the murine homologues of colorectal cancer associated proteins (CCAP) such as hemoglobin, haptoglobin, hemopexin, alpha-2-macroglobulin and cadherin-17 have been identified, demonstrating the potential of fecal proteomics for detecting potential biomarkers and paving the way for subsequent MS/MS based biomarker studies on similar human samples.
Collapse
Affiliation(s)
- Ching-Seng Ang
- Ludwig Institute for Cancer Research, Melbourne Tumour Biology Branch, PO Box 2008, Royal Melbourne Hospital, Australia
| | | | | | | | | |
Collapse
|
85
|
Urinary Proteome Analysis using Capillary Electrophoresis Coupled to Mass Spectrometry: A Powerful Tool in Clinical Diagnosis, Prognosis and Therapy Evaluation. J Med Biochem 2009. [DOI: 10.2478/v10011-009-0020-0] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Urinary Proteome Analysis using Capillary Electrophoresis Coupled to Mass Spectrometry: A Powerful Tool in Clinical Diagnosis, Prognosis and Therapy EvaluationProteome analysis has emerged as a powerful tool to decipher (patho) physiological processes, resulting in the establishment of the field of clinical proteomics. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. Due to the enormous complexity of the proteome, a separation step is required for mass spectrometry (MS)-based proteome analysis. In this review, the advantages and limitations of protein separation by two-dimensional gel electrophoresis, liquid chromatography, surface-enhanced laser desorption/ionization and capillary electrophoresis (CE) for proteomic analysis are described, focusing on CE-MS. CE-MS enables separation and detection of the small molecular weight proteome in biological fluids with high reproducibility and accuracy in one single processing step and in a short time. As sensitive and specific single biomarkers generally may not exist, a strategy to overcome this diagnostic void is shifting from single analyte detection to simultaneous analysis of multiple analytes that together form a disease-specific pattern. Such approaches, however, are accompanied with additional challenges, which we will outline in this review. Besides the choice of adequate technological platforms, a high level of standardization of proteomic measurements and data processing is also necessary to establish proteomic profiling. In this regard, demands concerning study design, choice of specimens, sample preparation, proteomic data mining, and clinical evaluation should be considered before performing a proteomic study.
Collapse
|
86
|
Svetlov SI, Larner SF, Kirk DR, Atkinson J, Hayes RL, Wang KKW. Biomarkers of blast-induced neurotrauma: profiling molecular and cellular mechanisms of blast brain injury. J Neurotrauma 2009; 26:913-21. [PMID: 19422293 DOI: 10.1089/neu.2008.0609] [Citation(s) in RCA: 67] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
Abstract
The nature of warfare in the 21st century has led to a significant increase in primary blast or over-pressurization injuries to the whole body and head, which manifest as a complex of neuro-somatic damage, including traumatic brain injury (TBI). Identifying relevant pathogenic pathways in reproducible experimental models of primary blast wave exposure is therefore vital to the development of biomarkers for diagnostics of blast brain injury. Comparative analysis of mechanisms and putative biomarkers of blast brain injury is complicated by a deficiency of experimental studies. In this article, we present an overview of current TBI biomarkers, as well as outline experimental strategies to investigate molecular signatures of blast neurotrauma and to develop a pathway network map for novel biomarker discovery. These biomarkers will be effective for triaging and managing both combat and civilian casualities.
Collapse
Affiliation(s)
- Stanislav I Svetlov
- Center of Innovative Research, Banyan Biomarkers, Inc. 12085 Research Drive, Alachua, FL 32615, USA.
| | | | | | | | | | | |
Collapse
|
87
|
Izrael-Tomasevic A, Phu L, Phung QT, Lill JR, Arnott D. Targeting interferon alpha subtypes in serum: a comparison of analytical approaches to the detection and quantitation of proteins in complex biological matrices. J Proteome Res 2009; 8:3132-40. [PMID: 19351188 DOI: 10.1021/pr900076q] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
The targeted detection and quantitation of proteins in complex biological fluids such as blood is as analytically challenging as it is crucial for biomedical research. Antibody-based techniques such as the ELISA are the current standards for such measurements, having in favorable cases high specificity and pg/mL detection limits. Long development timelines and susceptibility to cross reactivity have led researchers to investigate mass spectrometric alternatives. The literature contains diverse schemes for sample preparation and multiple platforms for mass spectrometric detection. Critical evaluations of competing technologies are, however, badly needed. Taking closely related subtypes of the pro-inflammatory cytokine interferon alpha as a test case, we compared a sample preparation workflow based on affinity enrichment to one based on generic multidimensional chromatography, and evaluated mass spectrometric techniques using tandem mass spectrometry on low resolution ion traps, high resolution "accurate mass tags," and triple quadrupole selective reaction monitoring. Each workflow and detection method proved capable of detecting and discriminating between these proteins at or below the ng/mL level in human serum. Quantitation by isotope dilution was evaluated using full length protein as the internal standard. Both triple quadrupole selected reaction monitoring and orbitrap selected ion monitoring produced linear calibration curves from 1 ng/mL to 1 microg/mL, with lower limits of quantitation below 5 and 50 ng/mL, respectively.
Collapse
Affiliation(s)
- Anita Izrael-Tomasevic
- Protein Chemistry Department, Genentech Inc., South San Francisco, California 94080, USA
| | | | | | | | | |
Collapse
|
88
|
Industrialized MS-based proteomics in the search for circulating biomarkers. Bioanalysis 2009; 1:1149-63. [DOI: 10.4155/bio.09.105] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Proteomics is the study of the expression, structure and function of proteins under a range of cellular conditions. A rapidly evolving component of this field is clinical proteomics, which focuses on proteins involved in human disease and how they are affected by therapeutic intervention. MS is the main analytical technology for identifying and quantifying proteins whose expression is modulated across the normal to disease continuum. Applying this technology to clinical samples, however, is particularly challenging due to high biological variability in the population, a variety of disease stages, nonuniform response to therapy, multiple concomitant treatments and special requirements for handling samples from clinical trials. Given these challenges, an ‘industrialized’ approach is best suited to clinical biomarker development, with its standard operating procedures, process control and ‘chain of custody’. This review will focus, therefore, on MS-based industrialized proteomics for the discovery and verification of circulating candidate clinical protein biomarkers.
Collapse
|
89
|
Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. MASS SPECTROMETRY REVIEWS 2009; 28:703-24. [PMID: 18973238 PMCID: PMC2720435 DOI: 10.1002/mas.20205] [Citation(s) in RCA: 128] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
Proteome analysis has emerged as a powerful technology to decipher biological processes. One of the main goals is to discover biomarkers for diseases from tissues and body fluids. However, the complexity and wide dynamic range of protein expression present an enormous challenge to separation technologies and mass spectrometry (MS). In this review, we examine the limitations of proteomics, and aim towards the definition of the current key prerequisites. We focus on capillary electrophoresis coupled to mass spectrometry (CE-MS), because this technique continues to show great promise. We discuss CE-MS from an application point of view, and evaluate its merits and vices for biomarker discovery and clinical applications. Finally, we present several examples on the use of CE-MS to determine urinary biomarkers and implications for disease diagnosis, prognosis, and therapy evaluation.
Collapse
Affiliation(s)
- Harald Mischak
- Mosaiques Diagnostics & Therapeutics, Hannover, Germany.
| | | | | | | | | | | |
Collapse
|
90
|
Abstract
PURPOSE OF REVIEW New disease-specific biomarkers are sorely needed within all fields of medicine. This review covers the current literature of biomarkers within pediatric urology and discusses future perspectives and directions for biomarker discovery. RECENT FINDINGS Biomarkers can be used to diagnose disease, monitor response, or sub-classify disease. Within pediatric urology, numerous markers for renal obstruction [ureteropelvic junction (UPJ)] and vesicoureteral reflux (VUR) have been identified and have shown initial promise; however, no markers have been rigorously validated or demonstrated to be clinically effective. Recent advances in proteomic technologies may provide a new discovery method to identify panels of markers for specific disease. SUMMARY New clinically significant biomarkers of UPJ or VUR that can improve the diagnostic capability or help determine risk for renal damage are sorely needed. However, rigorous clinical validation of previously identified markers has been limited. Other studies have demonstrated that combining various markers may help improve the ability to define clinical relevance. To improve biomarker discovery efforts, a combination of focused biomarker studies, potentially using new advanced proteomic technologies, and well designed clinical studies are needed.
Collapse
|
91
|
Reisdorph NA, Reisdorph R, Bowler R, Broccardo C. Proteomics methods and applications for the practicing clinician. Ann Allergy Asthma Immunol 2009; 102:523-9. [PMID: 19558013 DOI: 10.1016/s1081-1206(10)60128-7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
OBJECTIVE To describe clinical proteomics from discovery techniques and their limitations, to applications in allergy, asthma, and immunology, and finally to how proteomics can be integrated into clinical practice. DATA SOURCES Despite many inherent challenges, proteomics-based methods have become a powerful and popular means of profiling clinical samples for the purpose of biomarker discovery. Although several strategies exist, clinical proteomics for the purpose of biomarker discovery generally focuses on 1 of 3 basic workflows: (1) 2-dimensional gel electrophoresis to quantitate relative protein levels followed by mass spectrometry (MS) to identify proteins of interest, (2) non-gel-based methods that rely on liquid chromatography MS (LCMS) for both quantitation and identification of proteins, and (3) protein profiling methods that do not directly result in the identification of proteins but rather generate "fingerprints" that are compared among individuals or samples. STUDY SELECTION Regardless of the strategy being pursued, a few general experimental steps are followed that will be expounded on in the text. These proteomics techniques have been applied to discover new biomarkers in biofluids and tissues from individuals with a variety of conditions, including allergy, asthma, atopic dermatitis, inflammatory diseases, chronic obstructive pulmonary disease, and other lung diseases. RESULTS After biomarker discovery, LCMS-based proteomics offers several advantages over traditional antibody-based clinical assays, including greater specificity, cost- and time-effectiveness, and the potential to multiplex up to hundreds of peptides in a single assay. CONCLUSION With many guidelines now in place and model studies on which to design future experiments, there is reason to be optimistic that candidate protein biomarkers will be discovered using proteomics and translated into clinical assays.
Collapse
Affiliation(s)
- Nichole A Reisdorph
- Department of Immunology, National Jewish Health, Denver, Colorado 80206, USA.
| | | | | | | |
Collapse
|
92
|
Haudek VJ, Slany A, Gundacker NC, Wimmer H, Drach J, Gerner C. Proteome Maps of the Main Human Peripheral Blood Constituents. J Proteome Res 2009; 8:3834-43. [DOI: 10.1021/pr801085g] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- Verena J. Haudek
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| | - Astrid Slany
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| | - Nina C. Gundacker
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| | - Helge Wimmer
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| | - Johannes Drach
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| | - Christopher Gerner
- Department of Medicine I, Institute of Cancer Research, Medical University of Vienna, Austria, Section Biomedical Laboratory Science, University of Applied Science, Vienna, Austria, and Department of Medicine I, Department of Clinical Oncology, Medical University of Vienna, Austria
| |
Collapse
|
93
|
Vaezzadeh AR, Steen H, Freeman MR, Lee RS. Proteomics and opportunities for clinical translation in urological disease. J Urol 2009; 182:835-43. [PMID: 19616261 DOI: 10.1016/j.juro.2009.05.001] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2008] [Indexed: 12/15/2022]
Abstract
PURPOSE Proteomics is a rapidly growing new discipline that has the potential to increase and improve the understanding of protein function and interaction in the context of systems biology. As a translational science it has the potential to identify many new therapeutic targets as well as diagnostic and prognostic biomarkers of disease. Proteomics approaches consist of a combination of powerful technologies such as protein/peptide separation, identification and bioinformatic detection, and quantitation based on powerful computational data processing tools. We present an overview of current proteomics technologies, a review of proteomics applications in urology and a perspective on the future of proteomics in clinical medicine. MATERIALS AND METHODS A literature search was performed on the basic concepts of proteomics and technologies commonly used in this field. Advantages, challenges and limitations of current proteomics approaches are discussed, and proteomics applications in the field of urology are presented. RESULTS The proteomics approaches to answer clinical questions have only recently been introduced. Many different technologies have been used in this field, which is moving from simple description to quantitative clinical applications. CONCLUSIONS Proteomics offers new approaches to the study of genitourinary tract diseases, and the potential to identify clinically relevant biomarkers and new therapeutic targets.
Collapse
Affiliation(s)
- Ali R Vaezzadeh
- Department of Urology, Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts, USA
| | | | | | | |
Collapse
|
94
|
Pernemalm M, De Petris L, Eriksson H, Brandén E, Koyi H, Kanter L, Lewensohn R, Lehtiö J. Use of narrow-range peptide IEF to improve detection of lung adenocarcinoma markers in plasma and pleural effusion. Proteomics 2009; 9:3414-24. [DOI: 10.1002/pmic.200800814] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
|
95
|
Ahmed FE. The role of capillary electrophoresis–mass spectrometry to proteome analysis and biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:1963-81. [DOI: 10.1016/j.jchromb.2009.05.023] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2008] [Revised: 04/24/2009] [Accepted: 05/10/2009] [Indexed: 01/25/2023]
|
96
|
Brun V, Masselon C, Garin J, Dupuis A. Isotope dilution strategies for absolute quantitative proteomics. J Proteomics 2009; 72:740-9. [DOI: 10.1016/j.jprot.2009.03.007] [Citation(s) in RCA: 217] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2009] [Revised: 03/05/2009] [Accepted: 03/24/2009] [Indexed: 10/20/2022]
|
97
|
|
98
|
Miguet L, Béchade G, Fornecker L, Zink E, Felden C, Gervais C, Herbrecht R, van Dorsselaer A, Mauvieux L, Sanglier-Cianferani S. Proteomic Analysis of Malignant B-Cell Derived Microparticles Reveals CD148 as a Potentially Useful Antigenic Biomarker for Mantle Cell Lymphoma Diagnosis. J Proteome Res 2009; 8:3346-54. [DOI: 10.1021/pr801102c] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Laurent Miguet
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Guillaume Béchade
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Luc Fornecker
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Estelle Zink
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Claire Felden
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Carine Gervais
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Raoul Herbrecht
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Alain van Dorsselaer
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Laurent Mauvieux
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| | - Sarah Sanglier-Cianferani
- Laboratoire de Spectrométrie de Masse Bio-Organique, IPHC-DSA, UDS, CNRS, UMR7178, ECPM 25 rue Becquerel, 67087 Strasbourg, France, Laboratoire d’Hématologie cellulaire EA 3948, Institut d’Hématologie, Strasbourg, France, and Pôle d’Onco-Hématologie - Hôpitaux Universitaires de Strasbourg, France
| |
Collapse
|
99
|
Ahmed FE. Liquid chromatography–mass spectrometry: a tool for proteome analysis and biomarker discovery and validation. ACTA ACUST UNITED AC 2009; 3:429-44. [DOI: 10.1517/17530050902832855] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
100
|
Chen G, Pramanik BN. Application of LC/MS to proteomics studies: current status and future prospects. Drug Discov Today 2009; 14:465-71. [DOI: 10.1016/j.drudis.2009.02.007] [Citation(s) in RCA: 48] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2008] [Revised: 02/02/2009] [Accepted: 02/13/2009] [Indexed: 02/06/2023]
|